Our headquarter office is moved to Izumi Garden Tower 15F.
SBI Biotech’s Licensed product, an Anti-ILT7 antibody (MEDI7734) has achieved a Developmental Milestone in a Phase I Clinical Trial[Written in Japanese]
SBI Biotech’s Licensed product, an Anti-ILT7 antibody, has IND approval to initiate a Phase Ⅰ Clinical Trial(PDF/39KB)
SBI Biotech’s Subsidiary Quark Pharmaceuticals Doses First Patients in Two Pivotal Phase Ⅲ Studies and One Phase Ⅱ Study of RNAi-Based Therapeutics for Kidney and Eye Indications[Written in Japanese](PDF/154KB)
Announcement of new director.[Written in Japanese](PDF/119KB)
Announcement of change of top management.[Written in Japanese](PDF/84KB)